Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

NCT07594015 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Endometrial Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

University of Miami